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Summary
Objectives To determine whether serum Cystatin C (CysC) and
NTproBNP have prognostic value among patients with long-standing
chronic lung disease.
Design Prospective, observational, non-interventional study.
Setting CysC and NTproBNP are prognostic markers in several cardiac
conditions. In addition, CysC acts as an antiprotease following Cathepsin
activation, which has been involved in the pathogenesis of chronic
obstructive pulmonary disease.
Participants Patients with a basal functional status of II-IV (NYHA),
admitted for an acute exacerbation of chronic pulmonary diseases and no
previous history of symptoms related to pulmonary hypertension or heart
failure.
Main outcome measures NTproBNP and CysC were determined at
admission in 107 patients with acute exacerbation of chronic lung disease.
During 12-month follow-up, mortality, new hospital admissions and
prescription of diuretics were recorded.
Results During follow-up there were eight patient deaths (7.5%). Mean
NTproBNP among the deceased was 1510.20 pg/mL (95% CI 498.44–
4628.55) vs 502.70 pg/mL (95% CI 395.44–645.48) among survivors (p=
0.01). Twenty-seven patients (25%) were prescribed loop diuretics. Mean
concentration of CysC was 1.45 mg/dL (95% CI 1.21–1.69 mg/dL) vs
1.17 mg/dL (95% IC 1.09–1.25 mg/dL) in those not prescribed (p =0.004).
NTproBNP concentration was 837.14 pg/mL (95% CI 555.57–1274.10 pg/
mL) in patients prescribed diuretics vs 473.42 pg/mL (95% CI 357.80–
632.70 pg/mL) in those not prescribed (p =0.03). Kaplan-Meier analysis
revealed a signiﬁcant difference between death and diuretic prescription
during follow-up when cut-off value for NTproBNP was 550 pg/mL (p =
0.03 and p= 0.02, respectively). For 1.16mg/dL of CsysC, a signiﬁcant
difference was only observed in diuretic prescription (p =0.007).
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1Conclusions In patients with chronic respiratory diseases NTproBNP
has predictive value in terms of mortality whereas CysC does not. However,
it is still possible that both can contribute to the early identiﬁcation of
patients at risk of developing clinical ventricular dysfunction.
Introduction
Cardiac biomarkers are tools that should aid the
physician in one or more of the following: diagno-
sis and subsequent risk stratiﬁcation; risk stratiﬁ-
cation for secondary prevention; guiding
selection of therapy; and, ﬁnally, in some cases,
serving as a target for therapy. Among them,
natriuretic peptides (both BNP and NTproBNP)
are the most commonly used for diagnosis and
risk stratiﬁcation in patients with heart failure.
1,2
Another emerging biomarker, Cystatin C (CysC),
initially used for measuring renal function
3 is
becoming more frequent in the clinical setting,
since its serum levels add important prognostic
information when evaluating certain conditions
that go beyond the simple renal function estimate.
CysC has been found to be a more reliable predic-
tor of cardiovascular risk than either creatinine or
the estimated GFR among the elderly,
4,5 and also
provide signiﬁcant prognostic information, in
terms of morbidity and mortality, among coron-
ary,
6 hypertensive,
7 acute
8 and chronic
9 heart
failure patients.
10,11 CysC adds complementary
information to the data provided by NTproBNP
alone.
11,12
The potential usefulness of natriuretic peptides
(not of CysC) has also been tested in several respir-
atory conditions. Raised NTproBNP concen-
trations have been found in patients with chronic
lung diseases,
13 cor pulmonale
14,15 and pulmon-
ary embolism.
16 B-type natriuretic peptide was a
short-term independent predictor of mortality in
patients with chronic lung disease
13,17 and
primary pulmonary hypertension.
18
Chronic cor pulmonale is a complication of
chronic and severe lung diseases and an indepen-
dent predictor of death.
19 Early diagnosis and
treatment of cor pulmonale increases survival
rate and improves the patients’ quality of life.
20
Therefore, identiﬁcation of patients who are at
risk of suffering cor pulmonale could be beneﬁcial
for the management and prognosis of the disease.
One category of patients potentially at risk are
those who develop silent high arterial pulmonary
pressures during acute respiratory processesin the
absence of a history of heart disease.
We hypothesize that an increase in either
NTproBNP or CysC blood concentrations could
improve risk stratiﬁcation among patients with
acute exacerbations of CLD prior to onset of symp-
tomatic right heart failure. The aim of the study
was to determine the prognostic utility of
NTproBNP and CysC in this setting.
Patients and methods
Patients admitted consecutively due to acute
exacerbation of chronic pulmonary diseases, and
interviewed within 72 hours of admission, were
included in the study. Chronic pulmonary diseases
considered eligible were: chronic obstructive pul-
monary diseases (COPD); chronic bronchitis;
emphysema; chronic asthma; pulmonary ﬁbrosis;
and pneumoconiosis. Patients considered eligible
had a basal functional status of II-IV (NYHA) and
no previous history of symptoms related to pul-
monary hypertension orrightheart failure.Patients
diagnosed with heart failure, valvular heart
disease, acute or chronic pulmonary embolism,
symptomatic ischemic heart disease, renal failure
(creatinine >2m g /mL), liver cirrhosis, hyperthyr-
oidism and Cushing’s syndrome were excluded.
Patients treated with diuretics (for whatever
reason) were also excluded, with the exception of
hypertensive patients treated with low dose
(12.5 mg or equivalent) hydrochlorotiazide.
The study was carried out in the Internal Medi-
cine Units of the Hospital Clı ´nico Universitario
Lozano Blesa, Zaragoza, and Hospital ‘Virgen de
la Luz’, Cuenca, Spain. The study protocol was
checked and approved by the region’s Ethics
Committee (Comite ´ E ´tico de la Comunidad
Auto ´noma de Arago ´n [CEICA]) under reference
code PI-04/16. Signed consent was obtained
from each patient. Neither speciﬁc interventions
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Variables
The patients were interviewed and baseline demo-
graphic and clinical data prospectively obtained.
Data from laboratory and radiology studies were
also registered.
Outcomes were assessed at six-month intervals
during a follow-up period of at least one year.
Data were obtained by revising medical records,
outpatient clinic notes, telephone interviews,
hospital administrative ﬁles and oxygen-delivery
company ﬁles. For patients impossible to locate,
we used the ‘I ´ndice Nacional de Defunciones del
Ministerio Espan ˜ol de Sanidad y Consumo’, a
nation-wide database of deaths kept by Spain’s
Ministry of Health and Consumption.
A speciﬁc record was made of the following
data: date of death; cause of death; date on
which signs or symptoms of HF were ﬁrst
recorded; date of initial use of diuretics; date of
new admissions to hospital; and in-hospital days.
NTproBNP
Within 72 hours of admission, fasting blood
samples were drawn, centrifuged at 3000 rpm for
15 minutes, and plasma aliquots immediately
stored at –70˚C. All samples were processed
sequentially, in one session, in the same clinical
laboratory. Plasma NTproBNP was determined
by electro-chemo-luminescence immunoassay
(Elecsys proBNP 2010, Roche Diagnostics). The
system was calibrated whenever a new reactive
kit was used. Quality control was performed by
processing two control levels (either for high or
low values) in each series (Precicontrol Cardiac
Elecsys 1 y 2 Ref. 12018209122). This test is not
interfered with by hyperbilirubinaemia, haemoly-
sis, hyperlipaemia, biotin or rheumatoid factor to
1500 IU/mL; measurement interval 5–35.000 pg/
mL; variation coefﬁcient 0.8–5.8%; functional sen-
sitivity less than 5.9 pmol/L.
Cystatin C
Serum Cystatin C levels were measured by the N
latex Cystatin C assay on a BN II System (Dade
Behring GmbH, Marburg, Germany). This is a
latex-enhanced nephelometric immunoassay
using rabbit polyclonal antibodies.
21 Within-run
and between-run coefﬁcients of variation were
1.8% in a concentration range between 0.87–
4.65 mg/L.
Statistical analysis
Baseline characteristics of the patients are pre-
sented as percentages, for dichotomous variables;
or median value, with its interquartile range, for
continuous variables. For all variables, a normal
distribution was veriﬁed using histograms and
Kolmogorov–Smirnov test. Non-normally distrib-
uted values (NTproBNP) were logarithmically
transformed. Sperman rank correlation coefﬁcient
between age, NTproBNP, CysC and creatine was
calculated. The univariate analysis for continuous
variables was performed with the use of Student’s
T test. Analysis for categorical variables was per-
formed with χ2 test.
Survival curves were generated by means of
Kaplan-Meier estimates, and differences in survi-
val were compared with use of the log-rank test.
The ability of serum CysC and NTproBNP con-
centration to distinguish between patients who
will either die or be prescribed diuretics in the
year following discharge was evaluated by
means of descriptive statistics and receiver-
operating characteristic (ROC) curves. The area
under the ROC curve (AUC) and 95% conﬁdence
intervals were calculated.
All statistical procedures were carried out with
Statistical Package for the Social Sciences (SPSS),
version 11.5.
Results
One hundred and seven patients with acute
chronic lung disease exacerbation were enrolled
during the inclusion period (1 November 2004–
1 May 2006) and followed for one year (until
May 2007). Eligibility was determined by admis-
sion for a recent recrudescence of their respiratory
symptoms, usually an increase in the degree of
dyspnoea and hypoxemia or the worsening of an
existing one.
The general characteristics of the sample are
shown in Table 1; 82.2% were men, and 17.8%
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3women. The most frequent causes of chronic lung
disease were smoking related diseases (COPD)
(69%), chronic asthma (20.5%) and the rest
(10.5%) had either pulmonary ﬁbrosis or pneumo-
coniosis. Acute exacerbations were mostly due to
non-pneumonic respiratory tract infection in over
95% of cases.
The correlation coefﬁcient between CysC and
creatinine concentrations was 0.59 (p<0.001).
Between CysC and age it was 0.31 (p=0.001).
Between CysC and urea it was 0.68 (p<0.001) and
between CysC and NTproBNP it was 0.24 (p=
0.012). The correlation between NTproBNP, creati-
nine and urea was not statistically signiﬁcant. Age
showed a signiﬁcant correlation with urea (r =
0.23, p =0.017), with creatinine (r=0.26, P =0.006)
and with NTproBNP (r=0.34, p <0.001). The cor-
relation coefﬁcient between creatine and urea was
0.59 (p <0.001).
During the 12-month follow-up period, eight
patient deaths occurred (7.5%). Mean NTproBNP
concentration among the deceased was 1510.20
pg/mL (95 CI% 498.44–4628.55) vs 502.70 pg/
mL (95 CI% 395.44–645.48) among the survivors.
This difference was statistically signiﬁcant (p =
0.01).
Survival Kaplan-Maier curves showed signiﬁ-
cant differences for a cut-point value of
NTproBNP of 550 pg/mL (p =0.03) (Figure 1a).
Cut-off point was obtained by ROC analysis for
the prediction of one-year mortality for different
concentrations of NTproBNP. The selected cut-off
value had a sensitivity of 87.5%, a speciﬁcity of
50.5% and AUC of 0.74 (95% CI 0.56–0.92, p =
0.02).
Mean concentration of CysC at admission
among dead patients was 1.49 mg/dL (95% CI
media 1.00–1.98 mg/dL) and 1.22 mg/ dL (95%
CI media 1.13–1.31 mg/dL) among survivors.
This difference was statistically non-signiﬁcant
(p= 0.1). Survival Kaplan-Maier curves showed
no signiﬁcant difference for a CysC concentration
cut-off of 1.16 mg/dL (p =0.78) (Figure 1b). After
a follow-up period of one year, there were no sig-
niﬁcant differences in urea and creatinine concen-
trations between the group of survivors and the
group of deceased patients.
During the 12-month follow-up period, 29
patients (27%) were readmitted due to acute
exacerbation of their respiratory illness. Mean con-
centration of NTproBNP among patients read-
mitted was 632.70 pg/mL (95% CI media
391.50–1022.49 pg/mL) vs 518.01 pg/mL (95%
CI media 391.50–685.39 pg/mL) among non-
hospitalized (p =0.46).
Mean concentration of CysC among patients
needing hospitalization, during follow-up, was
1.28 mg/dL (95% CI media 1.13–1.43 mg/dL) vs
1.23 mg/dL (95% CI media 1.12–1.33 mg/dL)
among non-hospitalized ones (p =0.59).
During the 12-month follow-up period, 27
patients (25%) were prescribed with loop diure-
tics, due to appearance of leg or pedal oedema.
In univariate analysis, admission NTproBNP con-
centration was predictive of indication of diuretics
during follow-up. Admission NTproBNP concen-
tration was 837.14 pg/mL (95% CI media 555.57–
1274.10 pg/mL) among those patients who were
prescribed vs 473.42 pg/mL (IC 95% media
357.80–632.70 pg/mL) among those not pre-
scribed during follow-up (p =0.03). Serum con-
centration of CysC was also predictive of ‘de
novo’ prescription of diuretics during the
12-month follow-up period. Patients who received
diuretics during follow-up had a mean concen-
tration of CysC of 1.45 mg/dL (95% CI media
1.21–1.69 mg/dL) vs 1.17 mg/dL (95% IC media
Table 1
General characteristics of patients at baseline
Median
value
Interquartile
range
Age (years) 77 71–80
PaO2 (mmHg) 57.15 52.92–66.15
PaCO2 (mmHg) 37.65 33.92–43.52
HCO
3 (mmol/L) 26.35 24.10–29.07
Haemoglobin (g/dL) 14 12.6–15.2
Leukocyte count
(10
3/mm3)
11.10 7.9–13.7
Albumin (g/dL) 3.6 3.15–3.9
Total protein (g/dL) 6.5 5.9–7.1
Glucose (mg/dL) 124 100–155
Sodium (mEq/L) 139 137–141
Potasium (mEq/L) 4.3 4.02–4.7
Blood urea (mg/dL) 47 38–58
Creatinine (mg/dL) 0.9 0.7–1.0
NTproBNP (pg/mL) 573.76 199.32–1348.6
Cystatin (mg/dL) 1.11 0.95–1.43
PaO2 =arterial oxygen pressure; PaCO2 =arterial
carbon dioxide pressure; NTproBNP=N-terminal
fragment of pro BNP
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Cumulative survival according to NTproBNP (top panel) and CysC (bottom panel) concentrations at
admission. Solid line denotes a baseline concentration of NTproBNP above 550 pg/mL. Dotted line
denotes a baseline concentration of NTproBNP below 550 pg/mL (top panel). Solid line denotes a
baseline concentration of CysC above 1.16 mg/dL. Dotted line denotes a baseline concentration of CysC
below 1.16 mg/dL (bottom panel)
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51.09–1.25 mg/dL) in those who were not pre-
scribed diuretics (p = 0.004).
Admission creatinine concentrations were not
predictive of ‘de novo’ indication of diuretics
during the same period. Mean creatinine concen-
tration of patients prescribed diuretics was
0.98 mg/dL (95% CI media 0.85–1.11 mg/dL) vs
0.91 mg/dL (95% CI media 0.85–0.97 mg/dL)
among those not prescribed (p =0.251).
Nine (15%) of 59 and 19 (37.5%) of 48 patients
with a concentration of CysC at admission below
or above 1.16 mg/dL, respectively, were pre-
scribed with diuretics during the one-year
follow-up period (p =0.008). Predictive value of
CysC concentration for diuretics prescription at
one year was studied by means of ROC analysis
so as to ascertain sensitivity and speciﬁcity. AUC
was 0.633 (95% CI 0.514–0.753; p = 0.04). The
best cut-off point was 1.16 mg/dL (sensitivity
66.6% and speciﬁcity 62.5%).
Kaplan-Meier analysis of diuretics prescription
during follow-up, taking a cut-off value for CysC
of 1.16 mg/dL, showed a signiﬁcant difference
between survivors and deceased (p =0.007). A
cut-off point of 550 pg/mL for NTproBNP, also
showed signiﬁcant differences in prescription of
diuretics during follow-up (p= 0.02) (Figure 2a
and 2b). Diuretics were less frequently prescribed
among patients in whom concentrations of either
of the two biomarkers were below the selected
cut-off point.
Deaths and readmissions were assessed
through revision of hospital records. For cases
(25 patients) without follow-up records, a tele-
phone interview was conducted. It was answered
by 13 patients or relatives. For death occurrence
we also reviewed the ‘I ´ndice Nacional de Defun-
ciones del Ministerio Espan ˜ol de Sanidad y
Consumo’. No cases of death were overlooked;
although it is possible we might have excluded
some of the readmissions among the 12 patients
we were unable to locate. For ‘de novo’ diuretic
prescription we used data from discharge reports
or outpatient clinic notes or telephone interviews.
Discussion
In our study, we included patients previously
diagnosed with chronic lung disease (chronic
bronchitis, emphysema and chronic asthma
accounted for more than 90%) – the majority,
with a prior smoking habit. COPD involves a
chronic inﬂammation that leads to ﬁxed narrow-
ing of small airways and alveolar wall destruction
(emphysema). This is produced by the release of
multiple inﬂammatory mediators, including
serine proteases, cathepsins and matrix
metalloproteinases.
22,23
In our cohort of patients, NTproBNP was sig-
niﬁcantly higher in the deceased than in the survi-
vors, while CysC failed to predict mortality at 12
months after discharge for acute exacerbation.
However, both NTproBNP and CysC were signiﬁ-
cantly higher among patients who were more
likely to be prescribed diuretics during follow-up.
Since 20–30% of COPD
24 patients suffer from
heart failure as co-morbidity, it is possible that
an underlying, clinically silent, heart failure may
possibly explain these results. However, clinical
signs of heart failure were excluded by means
of a thorough physical examination performed
by two experienced physicians. All patients
with rales, jugular distension, oedema or liver
enlargement were ruled out prior to inclusion.
Consequently, although some patients with
asymptomatic ventricular dysfunction may have
been included, overt heart failure was certainly
excluded.
There are two possible explanations for the ‘de
novo’ prescription of diuretics. Firstly, CysC may
merely be a good measurement of renal function,
thereby predicting a higher degree of renal func-
tion decline that leads to ﬂuid retention, oedema
and prescription of diuretics. However, this
explanation seems unlikely in our series, since sig-
niﬁcant renal dysfunction was an exclusion cri-
terion and the creatinine concentration of most of
the patients was within a normal range and
below 2 mg/dL in all cases. In addition, neither
creatinine nor urea correlated with diuretic
prescription.
Secondly, above certain concentrations, both
NTproBNP and CysC may indicate a certain
degree of asymptomatic ventricular dysfunction
(either left side, right side or both sides). Patients
with a concentration of either NTproBNP or
CysC above a cut-off point of 550 pg/mL or
1.16 mg/dL, respectively, were more frequently
prescribed diuretics during the following six
months. We have recently shown, in a cohort of
192 patients with CLD followed for six months,
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6Figure 2
Cumulative interval free from diuretics according to NTproBNP (top panel) and CysC (bottom panel)
concentrations at admission. Solid line denotes a baseline concentration of NTproBNP above 550 pg/mL.
Dotted line denotes a baseline concentration of NTproBNP below 550 pg/mL (top panel). Solid line
denotes a baseline concentration of CysC above 1.16 mg/dL. Dotted linedenotes a baseline concentration
of CysC below 1.16 mg/dL (bottom panel)
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7that NTproBNP provided signiﬁcant prognostic
information. A concentration of NTproBNP
above 500 pg/mL increased the risk of death
11-fold, and above a concentration as low as 350
pg/mL, prescription of diuretics was three-fold
that of patients below this level.
17 We could
hypothesize that ‘de novo’ prescriptions of diure-
tics could be a surrogate marker of ventricular
dysfunction, clinically manifested by the appear-
ance of oedema. If this interpretation were
correct, NTproBNP and CysC might act as early
predictors of subclinical ventricular dysfunction.
Itseems plausible that CysC is aspeciﬁc marker
of cardiovascular remodelling rather than the sys-
temic inﬂammation or the inﬂammation of any
speciﬁc organ. In a recent study of a group of 52
non-diabetic patients with advanced chronic
kidney disease, Font et al.
25 analysed the corre-
lation between renal function, CysC and markers
of inﬂammation (C-reactive protein [CRP],
Interleukin-6 [IL-6], ﬁbrinogen) or oxidative
stress (oxidized low-density lipoprotein [LDLox]
antibodies, paroxonase 1 [PON1]). CysC corre-
lated with either creatinine or eGFR, but not with
inﬂammatory or oxidative stress markers. By reg-
ulating protease activities, protease inhibitors
such as CysC, playa pivotal role in tissue remodel-
ling.
26 In fact, CysC serum levels have been shown
to be independently associated with left ventricu-
lar mass, concentricity and wall thickness
measured by magnetic resonance imaging
(MRI).
27
Limitations of the study: COPD patients
included in our study had been previously diag-
nosed following standard GOLD criteria.
However, a respiratory function test was not pro-
spectively performed, thereby limiting the
interpretation of our results. Heart failure was
ruled out according to clinical judgement. It
would have been possible to include subclinical
cases of heart failure, but even if this had been
done, the information yielded by the two bio-
markers would still have been signiﬁcant. The
cohort of patients included in the follow-up is
small in number, thus limiting the strength of
our conclusions. However, duration of follow-up
and methodology used for assessing outcomes
seem to be sufﬁciently accurate for us to draw
our preliminary conclusions.
In conclusion, our study suggests, that in
patients with acute exacerbation of chronic lung
disease, measurement of serum levels of
NTproBNP, but not CysC, may identify a group
of patients with high risk of death. However,
both can contribute to the early identiﬁcation of
patients at risk of developing clinical ventricular
dysfunction.
Further studies designed to elucidate the role of
NTproBNP and CysC in chronic respiratory dis-
eases are needed.
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